title: Fatty acid synthase is a marker of increased risk of recurrence in endometrial carcinoma.
abstract: OBJECTIVE
  To explore the expression of fatty acid synthase (FAS) and human erythrocyte glucose transporter 1 (GLUT1) in endometrial carcinomas and to detect associations with clinicopathological features and prognosis. FAS and GLUT1 are two molecules involved in energy supply of normal cells. These markers are overexpressed in neoplastic tissues because of their increased necessity of energy.
  
  
  METHODS
  Ninety-five patients with endometrial carcinoma were followed-up for an average period of 5 years. FAS and GLUT1 expressions were evaluated by immunohistochemistry on formalin-fixed paraffin-embedded tissues. Staining was determined with a semiquantitative method. Negative controls were obtained from patients submitted to hysterectomy for uterine prolapse.
  
  
  RESULTS
  Eighty-five cases were endometrioid, 7 were serous, and 1 was a mucinous carcinoma. Seventy-two cases (75%) were stage I, 12 (13%) were stage II, and 11 (12%) were stage III carcinomas. Sixteen (15%) carcinomas recurred. Nine patients (8%) died for cancer during the follow-up period. FAS expression was observed in 53 cases (56%). GLUT1 expression was observed in 32 (43%) cases. Statistical analysis revealed that FAS (P = 0.04) and stage (P = 0.001) of the disease were the only two independent predictors of recurrence. GLUT1 and other clinicopathologic parameters had no prognostic association.
  
  
  CONCLUSIONS
  FAS is a reliable marker of clinically aggressive endometrial carcinomas. The knowledge of FAS expression in endometrial carcinomas is an important finding that may stratify patients into selected groups and determine therapeutic approaches for patient care.
authors.affiliation: Dipartimento di Medicina Sperimentale e Patologia (Anatomia Patologica), Università di Roma "La Sapienza," Viale Regina Elena 324-00161 Rome, Italy.
authors.forename: Valeria
authors.initials: V
authors.lastname: Sebastiani
authors.forename: Paolo
authors.initials: P
authors.lastname: Visca
authors.forename: Claudio
authors.initials: C
authors.lastname: Botti
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Santeusanio
authors.forename: Gregorio Marco
authors.initials: GM
authors.lastname: Galati
authors.forename: Valentina
authors.initials: V
authors.lastname: Piccini
authors.forename: Barbara
authors.initials: B
authors.lastname: Capezzone de Joannon
authors.forename: Ugo
authors.initials: U
authors.lastname: Di Tondo
authors.forename: Piero Luigi
authors.initials: PL
authors.lastname: Alo
mesh_terms: D014408:Biomarkers, Tumor / Q000096:biosynthesis*; D016889:Endometrial Neoplasms / Q000201:enzymology* / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D064429:Fatty Acid Synthases / Q000096:biosynthesis*; D005260:Female; D005500:Follow-Up Studies; D051272:Glucose Transporter Type 1; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009004:Monosaccharide Transport Proteins / Q000096:biosynthesis; D009364:Neoplasm Recurrence, Local / Q000201:enzymology* / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis
chemical_list: D014408:Biomarkers, Tumor; D051272:Glucose Transporter Type 1; D009004:Monosaccharide Transport Proteins; C495677:SLC2A1 protein, human; D064429:Fatty Acid Synthases